HER-2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council
Conditions: Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2 Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Conditions: Advanced Solid Tumor; Advanced Breast Cancer; Metastatic Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Non-small Cell Lung Cancer Interventions: Drug: BGB-43395; Drug: Fulvestrant; Drug: Letrozole Sponsors: BeiGene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer
Conditions: Breast Cancer; Breast Carcinoma in Situ; Breast Cancer Female Interventions: Other: Exercise Regimen Sponsors: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials
Fisetin and Exercise to Prevent Frailty in Breast Cancer Survivors
Conditions: Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Early Stage Breast Carcinoma Interventions: Procedure: Biospecimen Collection; Other: Educational Intervention; Other: Exercise Intervention; Drug: Fisetin; Other: Physical Performance Testing; Drug: Placebo Administration; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: Jonsson Comprehensive Cancer Center; National Institutes of Health (NIH); National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
Exploring Cultural Acceptability of Community Breast Cancer Risk Assessment Among Hispanic Women in Maricopa County
Conditions: Breast Carcinoma; Breast Cancer; Breast Cancer Female Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
Mobile Health for Adherence in Breast Cancer Patients
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Breast Carcinoma; HER2-Negative Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma Interventions: Other: Electronic Health Record Review; Other: Health Promotion and Education; Procedure: Health Telemonitoring; Other: Interview; Behavioral: Patient Navigation; Other: Survey Administration; Other: Text Message-Based Navigation Intervention Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)
Conditions: Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Hormone Receptor-Positive Breast Carcinoma Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
MR Correlated Spectroscopic Imaging for Diagnosing Breast Cancer
Conditions: Benign Breast Neoplasm; Breast Carcinoma; Malignant Breast Neoplasm Interventions: Procedure: Diffusion Weighted Imaging; Procedure: Magnetic Resonance Spectroscopic Imaging Sponsors: Jonsson Comprehensive Cancer Center; U.S. Army Medical Research and Development Command; U.S. Army Medical Research Acquisition Activity Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Conditions: Hepatocellular Carcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancers; Esophageal Squamous Cell Carcinoma; Triple Negative Breast Cancer; Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer; Head and Neck Squamous-Cell Carcinoma Interventions: Drug: ABBV-400 Sponsors: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
Biomarkers to Detect Endocrine Therapy Resistance
Conditions: Metastatic Cancer; Breast Cancer; Lobular Breast Carcinoma Interventions: Drug: 18F-fluorofuranylnorprogesterone; Device: Liquid Biopsy; Device: Positron Emission Tomography/Computed Tomography Sponsors: University of Wisconsin, Madison Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
Conditions: Cancer; Solid Tumor; Thromboembolism; Cardiovascular Diseases; Immune System Diseases; Inflammatory Diseases; Colon Cancer; Breast Cancer; Prostate Cancer; Hepatocellular Carcinoma; Lung Cancer; Chemotherapy; Immunotherapy Interventions: Drug: Palbociclib; Drug: Rivaroxaban; Genetic: SNP Sponsors: Lebanese University; Haykel Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Conditions: Breast Cancer; Ovarian Cancer; Pancreas Cancer; Prostate Cancer; BRCA1 Mutation; BRCA-Mutated Ovarian Carcinoma; BRCA-Associated Breast Carcinoma; HRD Positive Advanced Ovarian Cancer Interventions: Drug: TNG348; Drug: Olaparib Sponsors: Tango Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
Genetic Testing to Improve Management of Patients Undergoing Breast Biopsy
Conditions: Breast Carcinoma Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Conditions: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma Interventions: Procedure: Biospecimen Collection; Drug: Cyclophosphamide; Drug: Doxorubicin; Biological: Durvalumab; Other: Genetic Testing; Procedure: Mammography; Drug: Paclitaxel; Other: Quality-of-Life Assessment Sponsor: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Conditions: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma Interventions: Procedure: Biospecimen Collection; Drug: Cyclophosphamide; Drug: Doxorubicin; Biological: Durvalumab; Other: Genetic Testing; Procedure: Mammography; Drug: Paclitaxel; Other: Quality-of-Life Assessment Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
